Skip to main content

Advertisement

Table 3 Cumulative malaria case incidence at 3, 6, 12, and 16 months after MDA

From: A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission

  Malaria cases Cumulative incidence (cases/1000 population; range between shehias)  
Time period Intervention (N = 10,944) Control (N = 12,307) Intervention Control p value
Baseline
 6 months (May–Nov 2015) 128 126 11.7; 7.7–16.1 10.2; 6.4–32.8 0.130
 12 months (May 2015–April 2016) 150 146 13.7; 9.8–19.6 11.9; 7.5–36.8 0.105
Post-MDA
 3 months (May–Aug 2016) 31 41 2.8; 0.0–10.3 3.3; 0.9–8.0 0.721
 6 months (May–Nov 2016)1 43 52 3.9; 0.0–13.1 4.2; 2.1–8.0 0.442
 12 months (May 2016–April 2017) 58 71 5.3; 0.0–13.1 5.8; 3.1–10.4 0.382
 16 months (May 2016–Aug 2017) 143 208 13.1; 5.4–28.0 16.9; 6.7–31.8 0.130
Post-MDA cases without travel history
 3 months (May–Aug 2016) 18 23 1.6; 0.0–9.3 1.9; 0.0–8.0 0.716
 6 months (May–Nov 2016) 22 29 2.0; 0.0–11.2 2.4; 0.9–8.0 0.277
 12 months (May 2016–April 2017) 31 41 2.8; 0.0–11.2 3.3; 1.1–8.0 0.315
 16 months (May 2016–Aug 2017) 109 160 10.0; 5.4–26.1 13.0; 2.7–30.8 0.279
  1. 1Primary outcome